Podcasts about evidence based medicine

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What if the secret to overcoming chronic fatigue, brain fog, and cellular aging lies within your mitochondria? In this episode of The Better Life, host Dr. Mary Ann Pinkston sits down with international speaker, researcher, and cellular medicine expert Dr. Gordon Crozier from the Crozier Clinic. Together, they dive deep beneath the surface of traditional medicine to explore how integrative, evidence-based approaches can truly revitalize your health. If you’ve been slamming methylated B vitamins for MTHFR mutations but still feel completely exhausted, this conversation is the missing piece of your puzzle. What You’ll Learn in This Episode: The Truth About NAD+: Why this vital cellular coenzyme is essential for DNA repair, intense detoxification, and mitochondrial energy. NAD+ vs. Precursors: The difference between raw IV NAD+ (and why it causes nausea) versus cutting-edge precursors like NMN and True Niagen. The Magic of Methylene Blue: How this powerful antiviral compound works in concert with NAD+ to supercharge the electron transport chain—and why you must take structured breaks from it. Deep-Dive Methylation: Why methylation goes far beyond MTHFR, impacting hormone breakdown, breast and prostate cancer prevention, and neurodegenerative risks. Natural NAD+ Boosters: How everyday habits like proper weight management, targeted protein intake, and consistent exercise naturally elevate your levels. The Danger of "Supplement Overload": Why less is often more, and the hidden risks of buying non-third-party tested supplements off the shelf. Important Safety Note: Dr. Crozier explains why compounding quality matters and highlights critical contraindications for Methylene Blue, including SSRIs (Serotonin Syndrome risk) and G6PD deficiencies. Connect with the Experts: Find Dr. Gordon Crozier: Learn more about his practice, research, and social media at CrozierClinic.com. Find Dr. Mary Ann Pinkston: Access past episodes, resources, and links discussed in today's show at drpbetterlife.com. See omnystudio.com/listener for privacy information.

Damiaan Denys is a professor of psychiatry at the University of Amsterdam and the co-editor of "Deep Brain Stimulation: A New Frontier in Psychiatry."------------Keep Talking SubstackSpotifyApple PodcastsSocial media and all episodes------------Support via VenmoSupport on SubstackSupport on Patreon------------(00:00) Early Fascination With Human Nature(02:18) Difficult Father and Survival Through Understanding People(04:07) Boredom With Protocolized Psychiatry(06:34) From Anti-Psychiatry to Evidence-Based Medicine(10:01) What Psychiatry Is Supposed To Do(12:27) Defining Mental Disorders and Cultural Relativity(15:42) Choosing Psychiatry's Biggest Mysteries(18:04) Human Nature as Fundamentally Problematic(20:07) OCD, Addiction, and Dopamine Theory(23:41) Deep Brain Stimulation Origins(26:08) Understanding Obsessions and Compulsions(29:31) How Brain Stimulation Alters Brain Circuits(33:12) Instant Personality Changes After Stimulation(36:41) The Woman Who Cleaned Sixteen Hours Daily(40:04) Self-Confidence as the Hidden Mechanism(43:17) One Root Behind Many Psychiatric Disorders(46:09) Why Deep Brain Stimulation Remains Rare(49:22) Building a Future Around DBS Treatment(53:06) The Three-Part DBS Treatment Team(56:14) Depression Patient Rediscovers Music and Art(58:47) DBS as Stimulation of the Mind(01:01:08) Fragility, Vulnerability, and Human Connection(01:05:18) Soul, Transcendence, and Psychedelic Experiences(01:08:42) Leaving Academia and Returning to Human Beings(01:11:36) Autonomy, Modern Life, and Resisting Comfort

In this conversation, Dr. Marc Smith shares his journey from hedge fund trading in New York's financial district to building an integrated ketamine psychiatry practice in California. After three years in finance doing trading and sales, Dr. Smith made the bold decision to completely pivot his career toward medicine, driven by a desire for purpose and meaning that his financial career couldn't provide.Dr. Smith's path took him through Columbia University for medical school, followed by psychiatry residency at USC, where he discovered his passion for interventional treatments like TMS and ketamine therapy. His unique perspective, having worked in both profit-maximizing finance and purpose-driven healthcare, provides valuable insights into the challenges of maintaining ethical medical practice in an increasingly commercialized healthcare environment.Dr. Smith's practice, Clear Ketamine + Psychiatry, represents an integrated model where he personally handles psychiatric evaluation, preparation therapy, ketamine treatment administration, and post-treatment integration sessions.What You'll Learn in This Episode· Career transition insights - How Dr. Smith navigated the complete pivot from finance to medicine, including the challenges and rewards of choosing purpose over profit in healthcare· Mental health crisis analysis - Dr. Smith's perspective on factors contributing to rising depression, anxiety, and suicide rates, including social isolation, technology impacts, and healthcare access barriers· Treatment-resistant depression understanding - Why 30% of patients don't respond to traditional antidepressants and how ketamine offers a different mechanism through NMDA receptor antagonism and neuroplasticity induction· Integrated practice model - Dr. Smith's unique approach combining psychiatric evaluation, preparation therapy, ketamine administration, and integration sessions all under one provider rather than outsourcing components· Intentions versus goals framework - How to help patients set internal emotional states they're striving for (intentions) alongside specific, measurable functional outcomes (SMART goals) for comprehensive treatment planning· Ketamine as catalyst concept - Understanding how ketamine works like "jumpstarting a car" to improve mood and motivation, while ongoing therapy and lifestyle changes provide the maintenance needed for sustained improvement· Ethical practice building - Dr. Smith's mission to combat ketamine stigma through evidence-based protocols while addressing concerns about recreational associations and inappropriate use in the field· Private practice autonomy benefits - How owning your own practice allows values-driven decisions that may conflict with profit maximization, contrasting with private equity-driven healthcare models· Business building practical advice - The importance of talking to other practice owners, understanding it's a marathon not a sprint, and knowing your limitations to outsource effectively· Biopsychosocial treatment approach - Addressing biological, psychological, and social elements of mental health through medications, therapy, exercise, sleep, nutrition, social connection, and nature exposureEpisode 58 show notes:00:00:00 - Teaser: Profit vs. Purpose in Healthcare 00:00:35 - Episode Introduction00:02:03 - Dr. Smith's Background: From East Coast to Medicine 00:02:30 - Career Transition: Three Years in Financial Industry 00:04:12 - Discovering Psychiatry Through Clinical Rotations 00:05:32 - Why Psychiatry: Deep Relationships and Human Connection00:08:50 - Tools in the Toolbox: TMS, Ketamine, and Treatment Options 00:09:30 - The Leap: Stepping Away from Finance Success 00:11:17 - The Marble Metaphor: Chiseling Away What We Aren't 00:12:46 - Self-Actualization and Gratitude in Medicine 00:14:01 - USC Residency and Academic Reception of Ketamine 00:16:54 - Evidence-Based Medicine and the Slow Pace of Change 00:19:17 - Mental Health Crisis: Social Isolation and Technology 00:22:50 - The Invisible Nature of Mental Health Challenges 00:25:28 - Private Equity vs. Patient Care: The Business Tension 00:30:18 - Private Practice Autonomy and Values-Based Decisions 00:32:15 - Clear Ketamine + Psychiatry: The Integrated Model 00:36:11 - Treatment Protocol: Six Sessions with Therapy Integration 00:37:56 - Ketamine as Jumpstart: The Car Analogy 00:42:00 - Intentions vs. Goals: Internal States and SMART Outcomes 00:46:30 - Ethical Standards and Combating Ketamine Stigma 00:50:15 - Practice Building Advice: Talk to Other Providers 00:52:55 - Rapid Fire Questions: Book Recommendation 00:54:52 - Last Meal 00:55:52 - Pickleball Obsession and the Philosophy of the Game 00:56:50 - Time Travel00:58:46 - Alternative Career01:00:04 - Advice to 20-Year-Old Self01:01:53 - Contact Information and Practice Details 01:03:03 - Final Thoughts: Gratitude and Evidence-Based Care 01:04:20 - Ending and ResourcesThanks for listeningConnect with Dr. Marc Smith at:Website: https://www.clearketapsych.comInstagram: @clearketapsych, @marcsmithmdLinkedIn: www.linkedin.com/in/marcsmithmdGoogle Maps: https://maps.app.goo.gl/GCHVy8q183c7WvfLA

Send us Fan MailPost-thrombotic syndrome (PTS) affects up to half of patients following deep vein thrombosis and can significantly impair quality of life. Yet treatment options have historically been limited.In this episode of CLOT Conversations, David Airdrie and Dr. Jameel Abdulrehman speak with Dr. Susan Kahn about the recently published C-TRACT trial in The New England Journal of Medicine.The trial evaluated whether endovascular therapy, including iliac vein stenting, could improve outcomes for patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction.Dr. Kahn discusses the rationale behind the study, key findings related to symptom burden and quality of life, the increased bleeding risk observed with intervention, practical patient selection considerations, and the unanswered questions that remain regarding long-term management after venous stenting.This episode provides clinicians with practical insights into one of the most important recent studies in the management of post-thrombotic syndrome.Reference:Vedantham S, Kahn SR, Marston WA, Weinberg I, Sista AK, Magnuson EA, Cohen DJ, Wasan SM, Razavi MK, Goldhaber SZ, Sanfilippo KM. Endovascular Therapy for Post-Thrombotic Syndrome—A Randomized Trial. New England Journal of Medicine. 2026 Apr 13.https://www.nejm.org/doi/abs/10.1056/NEJMoa2519001Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Jonathan Livingstone-Banks, University of Oxford, UK. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Jonathan Livingstone-Banks lecturer & senior researcher in evidence-based healthcare in the Nuffield Department of Primary Care Health Sciences, University of Oxford. Dr Livingstone-Banks is part of the Tobacco Addiction Group within the Centre for Evidence-Based Medicine. He carries out research in the field of tobacco control and evidence synthesis and is involved in many Cochrane Reviews on tobacco control topics. Dr Livingstone-Banks is also a philosopher interested in the philosophy of evidence-based healthcare. In the May podcast Jonathan Livingstone-Banks discusses the findings of his overview of systematic reviews on the impacts of e-cigarette flavours. This is set against the backdrop of the first market authorisation of non-menthol, non-tobacco flavoured e-cigarettes in the US. The overview of reviews includes 32 reviews, 11 of which are higher quality and 21 of lower quality, and covers 1967 primary studies. Jonathan Livingstone-Banks outlines how e-cigarette flavours have the potential to impact a range of outcomes including e-cigarette and combustible cigarette use, safety profile, appeal, and perceptions of harm and how these may differ across different population groups. Overall, he considers that the data on flavours is limited and the impacts of e-cigarette flavours on e-cigarette and cigarette use are inconclusive. Further studies are needed to shed more light on this topic. Reference for the overview of systematic reviews discussed in this podcast: Livingstone-Banks J, Travis N, Conde M, Chen Y(C), Zi P, Jarman H, et al. The impacts of e-cigarette flavours: An overview of systematic reviews. Addiction. 2025;120(7):1327-1344. https://doi.org/10.1111/add.70017 This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our searches for the EC for smoking cessation review carried out on 1st May 2026 found: 1 linked report (10.1186/s13063-026-09622-6). Our search for our interventions for quitting vaping review carried out on 1st May 2026 found: 1 new study (10.1016/j.acap.2026.103328) and 1 ongoing study (ACTRN12626000336381). For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in November 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub10/full For more information on the full Cochrane review of Interventions for quitting vaping published in November 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub3/full

Gary Taubes on Rethinking Diabetes: Diet, Insulin, and the History Behind Low-Carb Treatment: Journalist Gary Taubes is author of “Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments.” The book traces diabetes treatment history and argues that carbohydrate restriction was standard care from 1797 through the early 20th century until insulin therapy shifted practice toward drug-centered management and higher-carbohydrate diets. Taubes explains how insulin's discovery changed dietary priorities, how later technology (radioimmunoassay) revealed that most diabetes is type 2 with insulin resistance and high insulin rather than deficiency, and why giving more insulin can worsen weight gain. They discuss major trials (including ACCORD, ADVANCE, and Look AHEAD) that failed to show benefits from intensive drug-based glucose control, the influence of low-fat guidelines, Richard Bernstein's role in blood-glucose self-monitoring and low-carb control, controversies about obesity models, ketosis vs ketoacidosis, GLP-1 drugs, and LDL increases on ketogenic diets.

As the lines between the supplement industry, "biohackers," and medical professionals continue to blur, we with down live at MSS with Dr. Kay Durairaj to discuss why aesthetic providers must lead the charge in evidence-based longevity. We dive deep into the world of peptides—from the safety of GLP-1s to the "wild west" of unregulated research chemicals. Dr. Kay also reveals her latest clinical breakthrough: her "Mid-Face Miracle" for preventing the dreaded "Ozempic Face" by supporting facial fat pads. Whether you're curious about the future of topical anti-aging or worried about the FDA's increasing interest in the med spa space, this episode is a masterclass in staying ahead of the curve while protecting your medical license. The discussion includes: [02:47] The Biohacking Resurgence [04:49] The "Gym Bro" Influence vs. Modern Medicine [06:56] Evidence-Based Medicine and Licensing Risks [12:56] Protecting the Med Spa Reputation [19:12] FDA Outreach and Industry Perception [21:13] Treating Aging as a Disease [25:21] The "Mid-Face Miracle" and Ozempic Face

Milton Mills, M.D. explains that heme iron from animal products is automatically absorbed and can lead to excess iron, increasing risk for cancer, heart disease, and diabetes. #IronOverload #HemeIron #ChronicDisease #HealthTalks

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we cover EBM updates concerning the imaging and management of adult appendicitis.  See part 1 for history and exam findings, laboratory testing, and risk diagnostic scores. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle PlaySend us Fan Mail

Cardiologists Bob Harrington and Lisa Rosenbaum discuss the loss of trust in medicine, how it may reflect patients' desire for agency, and strategies to earn it back. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington Taking Our Medicine — Improving Adherence in the Accountability Era https://doi.org/10.1056/NEJMp1307084 Full Coverage for Preventive Medications after Myocardial Infarction (MI FREEE trial) https://doi.org/10.1056/NEJMsa11079 Dr Rosenbaum's Not Otherwise Specified Podcast https://not-otherwise-specified-podcast.nejm.org/ The Concierge Cure? https://doi.org/10.1056/NEJMms2510427 Medical Education in the United States and Canada – Flexner https://doi.org/10.1126/science.32.810.41 The Importance of Being – Abraham Verghese https://doi.org/10.1377/hlthaff.2016.0837 Evidence-Based Medicine https://doi.org/10.1136/bmj.312.7023.71 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Dr Xinxin Yang, University of Oxford, UK. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Xinxin Yang. Dr Xinxin Yang is a qualitative researcher in the Department of Primary Care Health Sciences, University of Oxford. She is part of the Tobacco Addiction Group within the Centre for Evidence-Based Medicine. Dr Xinxin Yang is a Conversation Analyst on the TRIDENT (Tobacco RIsk reDuction with E-cigarette Nicotine Replacement Therapy) project, which aims to develop and deliver tailored smoking harm reduction interventions for people with serious mental illness in routine mental healthcare. In the April 2026 podcast Xinxin talks to Nicola Lindson about conversation analysis work on the MaSC study (Management of Smoking in Primary Care). In the MaSC study usual care was compared to brief advice and an offer to try an e-cigarette. The numbers of participants who reduced and quit smoking were measured at follow-up. She describes how the findings from MaSC will be used to design a communication guide that will be used to train the clinical professionals to deliver the offer of an e-cigarette for the TRIDENT trial. In TRIDENT consultations between the clinicians delivering the offer of e-cigarettes to patients will then be recorded and analysed with conversation analysis. Xinxin explains how this will provide some of the first real-world evidence on how to deliver smoking reduction intervention effectively for people with serious mental illness. This could prove to be valuable for clinicians and also for the service users. The findings may feed into a larger scale trial to be conducted across the UK. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our searches for the EC for smoking cessation review carried out on 1st April 2026 found: 3 linked reports (10.1158/1940-6207.CAPR-25-0244, 10.1016/j.addbeh.2026.108672, 10.64898/2026.03.18.26348637). Our search for our interventions for quitting vaping review carried out on 1st April 2026 found: 1 linked report (10.2196/79667). For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in November 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub10/full For more information on the full Cochrane review of Interventions for quitting vaping published in November 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub3/full

Clinical guidelines are often written by drug-funded experts. Learn how bias creeps in and leads to overprescribing. #MedicalGuidelines #PharmaInfluence #EvidenceBias #HealthTalks

A minority of patients requiring blood transfusions are increasingly requesting ‘unvaccinated' blood in the United States, per a new report published in the journal Transfusion. Our studio guest today, genito-urinary consultant Vanessa Apea, explains how this can lead to potentially dangerous delays and higher risks.Presenter Claudia Hammond speaks to Dr Angela Wu, from the Centre for Evidence-Based Medicine and Oxford Tobacco Addiction Group at the University of Oxford, about a new overview of the best available evidence worldwide for smoking cessation. The study, published in the journal Addiction, has found that nicotine‑containing e‑cigarettes appear to be more effective for stopping people smoking than other interventions.We hear how metabolic liver disease could affect nearly 1.8 billion people by 2050, according to new research published in The Lancet Gastroenterology & Hepatology journal. The growing number of cases means that many people are at risk of developing serious complications, however, the study also found that although more people are developing the disease, the overall impact on health has remained stable due to advances in treatment and care.We also hear from BBC World Service reporter Sen Nguyen in Vietnam as Hanoi plans to pilot a new low-emission zone from July to tackle air pollution. We hear what the proposed changes are and with the prevalence of diesel motorbikes in the city, how prepared are residents, workers and businesses for this change?And Claudia and Vanessa discuss whether living with friends may quietly be altering your gut bacteria, following new research published in the journal Molecular Ecology.Presenter: Claudia Hammond Producer: Jonathan Blackwell and Hannah Robins

Dr. Hoffman continues his conversation with bioethicist and psychiatrist Dr. Aaron Kheriaty, author of “Making the Cut: How to Heal Modern Medicine.” 

Bioethicist and psychiatrist Dr. Aaron Kheriaty, author of “Making the Cut: How to Heal Modern Medicine,” discusses declining public trust in healthcare. Kheriaty describes his medical training and argues medicine has become an industrial, bureaucratic “turnstile” system that dehumanizes care, turns physicians into data-entry clerks, and relies on reimbursement-driven “guidelines” and narrow evidence-based medicine that favors costly pharmaceuticals. He proposes creating “parallel” grassroots medical institutions—such as direct primary care—analogous to homeschooling and Eastern European dissidents' “parallel polis,” since systemic reform from within is difficult. Kheriaty recounts opposing COVID vaccine mandates at UC Irvine, being fired after suing, and participating in Missouri v. Biden and Ho v. Newsom, which challenged government-influenced social-media censorship and California's physician “misinformation” law. He also discusses informed consent, assisted suicide opposition, and advocating opt-in organ donation.

AI is rapidly reshaping pharmacy practice, raising both concern and opportunity for healthcare teams. Vizient host Kerry Schwarz is joined by Dr. Jason Chou, Vice President of the System Pharmacy Service Line, and Dr. Catherine Oliver, System AVP of Clinical Pharmacy Services at Ochsner Health, to explore how AI is improving efficiency while redefining how pharmacy teams spend their time. They discuss where technology is already making an impact and where its limits still require human expertise.   Guest Speakers:  Dr. Jason Chou, Pharm.D., MS Vice President, System Pharmacy Service Line Ochsner Health Dr. Catherine Oliver, Pharm.D., BCPS, DPLA, CPGx System AVP, Clinical Pharmacy Services Ochsner Health Host  Dr. Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence       Shownotes:  00:05 — Introduction Announcer welcomes listeners to VerifiedRx, produced by the Vizient Center for Pharmacy Practice Excellence.   00:14 — Episode Overview Host Kerry introduces the topic: the role of artificial intelligence (AI) in healthcare and pharmacy. Key themes: Addressing fears of job replacement Identifying real-world use cases Understanding limitations of AI Practical strategies for adoption Guests: Dr. Jason Chou, VP, System Pharmacy Service Line, Ochsner Health Dr. Catherine Oliver, System AVP, Clinical Pharmacy Services, Ochsner Health   01:04 — Will AI Replace Healthcare Jobs? Concern exists, but largely driven by misunderstanding AI is expected to: Augment, not replace, pharmacy roles Improve efficiency in daily workflows AI is not capable of: Independent clinical judgment Meaningful patient interactions Human elements—trust, empathy, and nuance—remain essential.   02:20 — Where AI Can Add Value Today Focus should shift from fear to practical use cases Ideal applications: Reducing non-value-added tasks Improving efficiency Supporting clinical decision-making preparation (not replacing it)   02:39 — Early Use Cases: Operational Efficiency AI can reduce administrative burden such as: Prior authorizations Insurance-related communications Data gathering and documentation Opportunity to eliminate “busy work” and improve staff satisfaction   03:31 — Clinical Workflow Support AI can: Summarize patient charts, labs, and notes Organize large volumes of clinical data Enables pharmacists to: Spend less time preparing Spend more time in patient care and provider interaction   04:08 — Additional Opportunities: Supply Chain & Operations AI can support: Inventory management Purchasing optimization Multi-site coordination Benefits include: Cost savings Improved efficiency Better resource utilization   05:00 — Where to Draw the Line AI should not replace clinical decision-making Limitations include: Lack of experience and judgment Inability to incorporate patient values and preferences Final decisions must remain with clinicians.   05:42 — Preserving the Human Element Patient care involves: Trust Empathy Relationship-building Over-reliance on AI risks eroding patient confidence.   06:11 — Patient Interaction & Transparency Patients want to know: When AI is used How it impacts their care Transparency and communication are critical   06:48 — AI in Direct Patient Care: Ambient Listening AI tools can: Capture conversations during patient visits Reduce documentation burden Important considerations: Patient consent Ability to opt out Privacy concerns   07:31 — Risks of Poor Implementation Poorly designed AI interactions can: Frustrate patients Reduce trust Healthcare AI must avoid: Impersonal experiences Inefficient automation 08:21 — AI as a Tool, Not a Replacement Comparable to tools like: Search engines (e.g., Google) Enhances efficiency without replacing professional roles.   09:12 — Early Success Stories Prior Authorization Optimization AI improves: Data extraction Documentation speed Approval timelines Benefits: Faster patient access to therapy Improved staff satisfaction   10:07 — Clinical Decision Support Enhancements AI-driven rule systems: Identify high-risk patients Reduce unnecessary chart reviews Example outcome: Reduction in time spent reviewing charts without intervention Frees pharmacists for: Medication reconciliation Patient counseling   11:11 — Impact on Workforce Engagement Staff report: Increased satisfaction More time for meaningful work AI seen as an enabler rather than a threat 12:03 — Vendor Landscape & Challenges Rapid growth of AI vendors addressing niche problems Key risks: Data security concerns Vendor quality variability Overlapping or redundant solutions   12:51 — Integration & Workflow Considerations Successful AI tools must: Integrate with EHRs Align with pharmacy workflows Avoid siloed systems Poor integration leads to inefficiency and adoption barriers   14:04 — Vendor Evaluation Considerations Assess: Clinical and operational expertise Product maturity Implementation effort Risk vs benefit Balance between: Ready-made solutions Custom-built tools requiring internal resources   14:56 — Practical Advice for Health System Leaders Develop a system-wide AI strategy Collaborate across departments (not siloed decisions) Engage: IT Legal Ethics teams Avoid duplicative solutions across service lines   15:31 — Building Organizational Readiness Be open to learning and experimentation Ask questions and maintain healthy skepticism Focus on: Improving workflows Enhancing patient outcomes Supporting workforce engagement   16:02 — Infrastructure & Speed of Innovation AI vendors move quickly Organizations must: Be prepared to adapt rapidly Avoid delays that hinder innovation Balance speed with governance and safety   16:27 — Closing Kerry thanks the guests for their insights Encourages continued exploration of AI's evolving role in healthcare Reminder to subscribe and engage with VerifiedRx.   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we cover Part 1 on EBM updates in acute appendicitis in adults. This part evaluates history and exam findings, laboratory testing, and diagnostic scoring systems. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Learn why only 4% of research targets health outcomes, and why most drug and device studies fail to reduce mortality. #MedicalResearch #HealthOutcomes #EvidenceBasedCare

Fifty to sixty percent of women will get a urinary tract infection at least once in their lifetime — and for many, it won't stop there. So why does almost every conversation about UTIs still end with the same answer: another antibiotic? In this episode of the Your Health University Podcast, host Jamie Preston sits down with Madison Browning, Executive Director of Clinical Services in the Specialty Department at Your Health, to explore what's actually possible when we stop reacting and start preventing. Madison oversees the urology and nephrology divisions and brings the kind of front-line clinical perspective that turns confusing medical information into something anyone can act on. Together, they cover: Why repeated antibiotic use can actually make you more prone to future infections — and what antibiotic resistance really means for your body The honest truth about cranberry: there is science behind it, but probably not in the form you've been using What D-Mannose is, how it works, and why it practically fills the hooks bacteria use to grab onto your urinary tract Vaginal estrogen — the most evidence-backed, most underused prevention option for postmenopausal women, and why the word "estrogen" shouldn't automatically trigger fear The lifestyle changes that cost nothing, require no prescription, and form the foundation of any prevention plan This isn't about abandoning medical care. It's about having a better conversation with your provider — one that goes beyond treating the infection in the moment and starts asking why it keeps happening at all. www.YourHealth.Org

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have transformed the treatment landscape across a wide variety of cancers, becoming foundational therapies in oncology. Dr. Stacey Sobocinski and Dr. Michele Rice join host Dr. Kerry Schwarz to discuss what the new subcutaneous PD-1/PD-L1 immune checkpoint inhibitors could mean for oncology practice. They cover the three agents that have become available in subcutaneous formulations, their advantages and disadvantages, other important operational, financial, clinical, and safety issues for health systems to consider.   Guest speaker:     Stacey Sobocinski, Pharm.D., BCPS Associate Director, Pharmacy Medication Management & Informatics MD Anderson Cancer Center    Michele Rice, Pharm.D., BCOP Senior Consulting Solutions Director Vizient Pharmacy Enterprise Solutions Host:   Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence     Show Notes: 00:05 — Introduction Announcer welcomes listeners to VerifiedRx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Kerry introduces the topic: new subcutaneous formulations of PD-1 and PD-L1 immune checkpoint inhibitors. These therapies have traditionally been administered intravenously (IV) in infusion centers. Recently approved subcutaneous versions include: Pembrolizumab (Keytruda Qlex) Nivolumab (Opdivo Qvantig) Atezolizumab (Tecentriq Hybreza) Potential benefits include shorter administration times and relief for infusion centers operating at capacity. Guests: Stacy Sobacinski, Associate Director of Pharmacy Medication Management and Informatics, MD Anderson Cancer Center Michelle Rice, Senior Pharmacy Enterprise Solutions Director, Vizient 01:39 — Clinical Data: Efficacy, Safety & Pharmacokinetics Subcutaneous formulations were approved in combination with hyaluronidase, allowing full-dose subcutaneous administration. Clinical studies demonstrated: Comparable pharmacokinetics Similar efficacy Similar safety profiles compared to IV formulations The main difference observed was local injection site reactions, expected with subcutaneous administration. 02:32 — Confidence in Clinical Comparisons Although direct head-to-head trials are limited, extensive experience with IV formulations supports confidence in safety and efficacy. Differences largely relate to administration method, not drug activity. 03:11 — Operational Impact: Changes to Workflow Subcutaneous administration introduces new operational considerations. Shorter injection times may appear advantageous, but real-world workflow impact is still being evaluated Much of a patient's visit still involves: Waiting room time Laboratory testing Provider visits Care coordination   04:06 — Chair Time vs Total Visit Time For therapies previously requiring longer infusions, switching to subcutaneous injections can significantly reduce chair time. For therapies previously infused over 30 minutes, the difference between IV and subcutaneous administration time may be less impactful.   04:24 — Administration Challenges Subcutaneous doses are not small-volume injections. Injection volumes may reach 10–15 mL Nursing considerations include: Patient tolerance for larger-volume injections. IV infusions allow nurses to start the infusion and attend to other tasks. Subcutaneous injections require continuous nursing presence during administration. This may increase direct nursing time.       05:05 — Equipment Considerations Some centers may use syringe pumps to administer subcutaneous injections. Many adult infusion centers do not currently have pumps since chemotherapy is typically delivered via IV using infusion pumps. Implementing syringe pumps could require additional equipment and associated procedures.   05:32 — Operational Complexity Transitioning to subcutaneous therapy involves more than simply switching order sets. Organizations must evaluate: Staffing models Nursing workflows Equipment availability Infusion center capacity management.   06:25 — Financial Considerations Subcutaneous formulations are currently priced roughly at parity with IV versions. Manufacturers may be incentivized to transition providers to subcutaneous formulations before biosimilars enter the market.   07:07 — Anticipating Market Dynamics Over time, pricing strategies may shift to encourage broader adoption. Biosimilar competition for these agents is expected within the next few years.   07:11 — Site of Care Considerations Adoption may vary by care setting: Hospital outpatient departments Physician offices Freestanding infusion centers   08:06 — Strategic Timing Decisions Health systems may weigh: Operational advantages of subcutaneous administration Potential cost reductions from future biosimilars Some organizations may delay adoption until biosimilar competition arrives.   08:24 — Infusion Center Optimization Subcutaneous therapies could increase turnover. Some centers may develop “express lanes” for subcutaneous administration.   09:01 — Payer Influence If subcutaneous formulations are perceived as cheaper or operationally simpler, payers may: Restrict site of care Prefer administrations in physician offices or non-hospital settings.   09:45 — Key Questions for Health Systems Organizations should consider: What value does the new dosage form provide? Which patients benefit most from subcutaneous administration? How will payer policies evolve?   10:05 — Evaluating Clinical Value Institutions often approach new dosage forms with caution. Subcutaneous PD-1/PD-L1 inhibitors may not offer the administration time reductions seen with other biologics because there is not as large of a difference in administration times (30 minutes versus 5 minutes).   10:53 — Patient Selection Considerations Subcutaneous formulations may be most beneficial for patients: Receiving monotherapy With difficult IV access Patients receiving combination therapies may see less benefit since IV access is already required.   11:12 — Additional Patient Factors Some patients have low body mass or cachexia, making high-volume subcutaneous injections more difficult. Physicians may prefer individualized treatment decisions rather than blanket formulary changes. 11:33 — Final Thoughts Transitioning to subcutaneous PD-1/PD-L1 inhibitors involves clinical, operational, and financial considerations. Observation times, administration practices, and workflow models continue to evolve. Ongoing monitoring of emerging best practices is encouraged. 12:15 — Closing ongoing monitoring of emerging best practices. Listeners are invited to subscribe and follow VerifiedRx for future episodes.   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

The MAHA backlash over RFK Jr.'s about-face on glyphosate; Amid the partisan divide, Making America Healthy Again cuts across party lines; New study confirms effectiveness of personalized lifestyle interventions for reversing dementia; After an allergic reaction to the Covid shot, is it safe to take other vaccines? Some GLP-1 users are developing scurvy; Six lifestyle hacks that augment weight loss drugs' cardio benefits.

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we cover myths and misconceptions in ectopic pregnancy testing including urine and serum β-hCG and ultrasound. Please see Part 1 for myths on risk factors, history, and exam.  To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

We're absolutely committed to being the most awkward section of the Archives of Disease in Childhood, and this month we're managing it with not only having a gender-indeterminate ‘voice' in this section and anthropomorphising a chunk of journal, but by leaping forward and backward in time. AI has not been involved with this writing, but we'll all be aware of where AI is creeping into our own professional and personal lives. Can it help in our high-quality evidence-based medicine, though? (Read more https://adc.bmj.com/content/111/2/193.2). Is it the future?  And looking to the past, should we be recommending breast milk for neonatal sticky eyes? And if not, why not? Again, a full explanation can be found in the journal: https://adc.bmj.com/content/111/2/193.1   We would love for you to be involved in Archi [https://adc.bmj.com/pages/authors#archimedes]. Just ask the questions that your patients are offering you - and tell us how you're finding the podcast offerings. Please listen to our regular podcasts and subscribe in your preferred platform to get episodes automatically downloaded to your phone and computer. And if you enjoy the ADC Podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832.

Vitamin D testing is vital for tailoring doses to optimize health—but regulators are conducting a campaign to deny coverage; Can magnesium be taken simultaneously with blood pressure meds? Lifelong learning delays Alzheimer's onset by 5 years; Your MRI says you have a bum shoulder—but 99% of people show abnormalities even when they have no discomfort; Saunas can help stave off dementia. 

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

The DUTCH test has become one of the most talked-about hormone assessments in the menopause space. Some women describe it as illuminating and empowering. Some medical professionals describe it as unnecessary, over-interpreted, or a waste of money.So why the disagreement?In this episode, I step back from the noise and explore what's actually being argued. What assumptions sit underneath functional hormone testing? What assumptions sit underneath conventional medicine? And why does this debate feel so emotionally charged?Rather than taking sides, we look at the psychological and structural differences between these two paradigms — and what happens when menopausal women find themselves caught in the middle.If you've ever felt validated by testing… dismissed by medicine… or confused by the intensity of the conversation online, this episode is for you.Join the waitlist for BECOMING

Highlights from the ANH conference in PhoenixWhat do you think of the supplements I'm taking for borderline osteoporosis?After years of vegetarianism, wouldn't eating meat cause adverse reactions like headaches or nausea?

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we cover myths and misconceptions in ectopic pregnancy, focusing on risk factors, history, and exam. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Why Real-World Use Doesn't Replace Trials; Placebo Effect and Clinical Trial Necessity; Raw Data Ownership Enables Manipulation; Empowering Patients Through Labels and Questions; Reading Drug Labels Reveals True Efficacy; Product Monographs as Trusted Resources; Many Widely Used Drugs Lack Long-Term Data; Limited Access to Raw Trial Data Even Through Labels; Therapeutics Initiative Offers Publicly Accessible Evidence; System Manipulation Persists in 2025; Covid Boosters Approved Without Efficacy Trials #PharmaTruth #EvidenceBased #MedicalEthics #HealthTalks

Is modern medicine still evidence-based, or have we quietly mistaken rigor for certainty?Evidence-based medicine is essential. It's why we save lives, advance care, and trust modern healthcare. But as medicine has become more specialized and disease more complex, something subtle has happened. Rigor has increasingly turned into reductionism, and evidence is often applied in ways that don't fully match the realities of clinical practice or patients' lived experiences.In this episode of The Trip Lab, I take a careful look at what we mean when we say “evidence-based medicine.” We explore the difference between statistical significance and clinical significance, how guidelines are created and why they are evidence-informed rather than infallible, and why many patients feel unwell despite having “normal” labs.This conversation also examines how modern research methods struggle to capture complexity, particularly in chronic, system-level disease. We look at where reductionism has helped medicine advance, where it now falls short, and why ancient healing systems and emerging fields like systems biology, functional medicine, and precision medicine are pointing us toward a more integrated future.This episode is not a rejection of evidence. It's an invitation to reclaim it. To restore clinical wisdom alongside data, and to practice medicine with both rigor and curiosity.In this episode, we cover:What “evidence-based medicine” actually means and how it's evolvedStatistical significance vs. clinical significanceThe strengths and limitations of medical guidelinesWhy reductionist models don't fully explain chronic diseaseWhy patients can feel unwell even when labs are “normal”How medicine might evolve to better study complexityWhy medicine is both a science and an artThe podcast name, The Trip Lab, nods to psychedelics, but a “trip,” psychedelic or otherwise, is ultimately an exploration. A willingness to step outside familiar frameworks, question what we think we know, and notice connections that weren't obvious before.If you've ever felt tension between what the data says, what the guidelines allow, and what the patient in front of you actually needs... or if you are a patient who has been failed by modern medicine, this episode is for you.

Three facts are scientifically undisputed: Serotonin is essential for fetal brain development. SSRIs disrupt the serotonin system. SSRIs freely cross the placenta. So why are pregnant women being told these drugs carry "little or no risk"?In this rare head-to-head debate, Dr. Adam Urato—maternal-fetal medicine specialist and FDA expert panelist—faces off against Dr. Robert Chen, a psychiatry resident willing to do what most of his colleagues won't: step into the arena and defend the establishment position.What unfolds is a striking conversation where both physicians actually agree on more than you'd expect—including that informed consent is failing pregnant women, that the chemical imbalance theory is dead, and that "untreated depression" is a misleading frame designed to sell drugs. The uncomfortable question neither side can fully answer: If SSRIs are correcting depression, why does the research show worse outcomes for women who stay on them?This isn't anti-medication propaganda. It's the conversation your doctor isn't trained to have with you.Listen before you fill that prescription. Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

We were all taught succinylcholine is contraindicated in hyperkalemia because it can cause potassium release, exacerbating the problem. But does it? Does it really?Dr. Jarvis discusses a recent paper that seems to compare mortality within 24 hours of RSI in hyperkalemic patients between those intubated with succ or rocuronium. And then we discuss methods.. including the Table 1 Fallacy. Citations:1.     Simmer PE, Perza M, Cho YD, et al.: Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: Retrospective study of clinical outcomes. The American Journal of Emergency Medicine. 2026; February;100:154–64.2.     Cole JB, Knack SKS, Driver BE: The value of P-values in “Table 1.” The American Journal of Emergency Medicine. 2026; February;100:182–6.3.     Pappal RD, Roberts BW, Mohr NM, et al.: The ED-AWARENESS Study: A Prospective, Observational Cohort Study of Awareness With Paralysis in Mechanically Ventilated Patients Admitted From the Emergency Department. Ann Emerg Med. 2021;77(5):532–44.4.     ‘Rick & Jerry' Pass the Baton | Emergency Physicians Monthly. Available at https://epmonthly.com/article/rick-jerry-pass-the-baton/. Accessed January 25, 2026.

John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information in Vizient's Center for Pharmacy Practice Excellence and Vizient's vaccine subject matter expert, joins host Stacy Lauderdale to discuss key updates to the CDC's childhood Immunization schedule and what they mean for practice.   Guest speaker:     John Schoen, PharmD, BCPS   Senior Clinical Manager of Evidence-Based Medicine and Drug Information    Vizient Center for Pharmacy Practice Excellence     Host:   Stacy Lauderdale, PharmD, BCPS   Associate Vice President  Vizient Center for Pharmacy Practice Excellence   Verified Rx Host    00:00 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Stacy Lauderdale introduces the topic: updates to the CDC's U.S. Childhood Immunization Schedule, revised January 20, 2026. Goal of the episode: explain what changed, what didn't, and what it means in practice for providers, pharmacists, and families. Guest: John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information at Vizient and vaccine subject matter expert. 01:16 — What Changed in the CDC Immunization Schedule CDC reorganized the schedule into three recommendation categories. Vaccines were reclassified, not removed. Number of diseases covered under “routine” recommendations decreased from 17 to 11 due to recategorization. 01:50 — Stated Rationale Behind the Changes Rationale provided in executive summary of scientific assessment. The supporting scientific assessment is available online and referenced for transparency (link in resources below). 03:19 — Were Any Vaccines Removed? No vaccines were removed from the CDC schedule. Some vaccines were shifted into different recommendation categories. 03:40 — Category 1: Routine Childhood Vaccinations Vaccines still routinely recommended for all children include: MMR (measles, mumps, rubella) Polio Tdap / DTaP Hib (Haemophilus influenzae type B) Pneumococcal HPV Varicella (chickenpox) 04:27 — Category 2: Vaccines for High-Risk Populations Vaccines recommended for children who meet specific high-risk criteria: RSV monoclonal antibodies (mAb) Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B Dengue 05:19 — What Changed vs. Stayed the Same Hepatitis A, Hepatitis B, and quadrivalent meningococcal moved from routine to high-risk RSV mAb recommendations are effectively unchanged, as high-risk infants are defined as those born to mothers who did not receive the maternal RSV vaccine. Dengue remains risk-based. Meningococcal group B remains a mix of risk-based and shared clinical decision-making. 06:31 — Category 3: Shared Clinical Decision Making (SCDM) Defined by ACIP as an individualized decision made jointly by provider and parent/guardian. Allows vaccination when risk-based criteria are not met but benefit is still considered. 06:52 — Vaccines Under SCDM Vaccines now include: Influenza COVID-19 Rotavirus Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B 08:05 — What's New in SCDM Influenza and rotavirus moved from routine to SCDM. Hepatitis A, hepatitis B, and quadrivalent meningococcal also shifted. COVID-19 moved to SCDM in September 2025 for individuals ≥6 months. 08:28 — Insurance Coverage Implications No expected changes in coverage. Vaccines recommended by CDC as of December 31, 2025 remain: Covered without cost-sharing under Affordable Care Act (ACA) plans. Covered by Medicaid, Children's Health Insurance Program (CHIP), and Vaccines for Children (VFC) program. 09:14 — Impact on Pharmacy Vaccine Access Pharmacists are considered healthcare providers under CDC SCDM definitions. Authority to administer vaccines primarily determined by state laws. Standing orders, protocols, and collaborative practice agreements may need to be updated, as applicable, to address language related to ‘routine' immunizations for children. 10:27 — Recommendations for Providers & Organizations For providers: Become familiar with schedule changes. Be prepared for patient and parent education. Recognize differences between CDC and other professional guidelines. For organizations: Review EHR documentation and order sets. Consult local state regulations to ensure compliance with vaccine administration practices. Review standing orders/protocols and collaborative practice agreements to determine if revisions are needed. Monitor vaccine utilization and adjust inventory accordingly. 11:24 — Resources & Closing Additional CDC and Vizient resources will be linked in the show notes. Announcer closes with subscription and feedback reminder. Links | Resources:    Additional resources HHS press release on changes to childhood immunizations schedule Assessment of US childhood and adolescent immunization schedule HHS fact sheet: CDC childhood immunization schedule Revised CDC child and adolescent immunization schedule ACIP shared clinical decision-making recommendations   Vizient resource Minute Market Insight   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

A conversation with Dr. Adam Cifu Find the video of this conversation at https://youtu.be/pmXHAobMXrU Find more from Dr. Cifu at https://www.adamcifu.com/ #medicine #neurosurgery #evidence #evidencebasedmedicine

 Endotrachael intubation is a highly important critical care procedure, and as such, clinicians are working to improve the procedure to ensure the best patient outcomes. As Stephanie DeMasi, MD, MS, assistant professor of emergency medicine at Vanderbilt University Medical Center, goes through the detailed review she wrote, along with her colleagues, on different evidence-based decisions clinicians face when intubating a patient, with host Eddie Qian, MD, Vanderbilt University Medical Center. Read Dr. DeMasi's paper, "Evidence-based Emergency Tracheal Intubation": https://www.atsjournals.org/doi/10.1164/rccm.202411-2165CI 

If you're wondering which therapies may influence care delivery, budgets, and decision making in 2026, the pipeline offers an early preview and it points to a year defined by innovation. We're seeing new first in class treatments, thoughtful next generation agents, and a biosimilar market where fewer launches are offset by important competitive shifts driven by recent approvals. John Schoen and Heather Pace from the Center for Pharmacy Practice Excellence join Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine and Drug Information and your Verified RX program host to highlight pipeline agents worth watching and discuss what they may mean for care delivery and spend management in the year ahead.   Guest speakers:  John Schoen, PharmD, BCPS   Senior Clinical Manager of Drug Information    Vizient Center for Pharmacy Practice Excellence    Heather Pace, PharmD Senior Clinical Manager of Drug Information    Vizient Center for Pharmacy Practice Excellence      Host:   Stacy Lauderdale, PharmD, BCPS   Associate Vice President  Vizient Center for Pharmacy Practice Excellence   Show Notes: 01:01 — Episode Scope The focus is non-CGT therapies; CGT pipeline will be covered in Part 2. 01:50 — Therapeutic Areas With the Most Approvals Oncology leads the pipeline. Others include infectious disease, neurology, rare disease, endocrine, hepatology, dermatology, and rheumatology. 02:37 — Biosimilars in 2026: Momentum or Headwinds? Discussion of potential “biosimilar void”—only 10% of expiring biologic patents have biosimilars in development. Emerging role of PBM private-label biosimilars. 03:51 — FDA Draft Guidance on Interchangeability FDA exploring interchangeable designation for all biosimilars. Potential shift away from clinical efficacy studies in favor of analytical comparisons. Guidance still in draft and open for public comment. 05:34 — John's Top Picks for First-in-Class Agents 06:11 — Orviglance First manganese-based, oral MRI contrast agent. Advantages for patients with kidney impairment. Used for liver imaging. 06:20 — Why Non-Gadolinium Matters Lower risk of nephrogenic systemic fibrosis. 06:46 — Tabelecleucel First allogeneic EBV-specific T-cell therapy. For EBV-positive PTLD post-transplant. Could become new standard of care. 07:42 — Tanruprubart First therapy specifically for severe Guillain-Barré Syndrome (GBS). Shows improved outcomes over IVIG and plasma exchange. 08:20 — Comparing to Standard of Care Review of improved real-world data outcomes. 09:03 — Therapies That May Shift Care Delivery 09:32 — Icotrokinra: First oral IL-23 antagonist for plaque psoriasis. 10:00 — Insulin Icodec First once-weekly basal insulin for type 2 diabetes. Resubmitted after safety concerns in type 1 diabetes. 10:59 — Honorable Mentions Camizestrant SERD for ER+/HER2– metastatic breast cancer. Ensitrelvir (COVID-19) Oral option for pre-exposure prophylaxis. Also being evaluated for treatment. Doravirine + Islatravir (HIV) Introduces new NRTTI class. Cefepime + Zidebactam Active against metallo-β-lactamase–producing organisms. 14:05 — Key Biosimilar Launches Omalizumab (Xolair) First biosimilars in asthma/allergy space. Aflibercept (Eylea) High competition expected pending litigation. Pertuzumab (Perjeta) First biosimilar anticipated in oncology. 15:31 — Biosimilars Approved in 2025, Impacting 2026 Ustekinumab (Stelara): first full year of competition Denosumab (Prolia/Xgeva): 10–15 biosimilars expected Eculizumab (Soliris): notable for rare disease market entry 17:17 — John's Closing Thoughts Strong mix of first-in-class advances and next-gen convenience therapies. 17:36 — Heather's Closing Thoughts 2026 will focus on speed and scale after the 2025 biosimilar wave. Pharmacists pivotal in ensuring smooth patient transitions.   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Episode 148 - Evidence in Practice - Nutritional Therapist Kirsten Chick looks at the development of Evidence Based Medicine, highlighting its strengths and weaknesses. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode is sponsored by Lightstone DIRECT. Lightstone DIRECT invites you to partner with a $12B AUM real estate institution as you grow your portfolio. Access the same single-asset multifamily and industrial deals Lightstone pursues with its own capital – Lightstone co-invests a minimum of 20% in each deal alongside individual investors like you. You're an institution. Time to invest like one._________________________________Are we all slowly “turning to plastic”?Professor Dr. Oliver Jones says: calm down. In this myth-busting episode of Succeeded In Medicine Podcast, Dr. Jones dismantles the fear around microplastics and “forever chemicals” (PFAS) with hard science and regulatory reality.Microplastics—defined as plastic particles

Pharmacy and Therapeutics (P&T) committees historically operated at the individual hospital level but have evolved into enterprise-wide governance programs due to health system expansion, unprecedented clinical and financial complexity of care, and the emergence of high impact and novel therapeutics. To address this, the Vizient Center for Pharmacy Practice Excellence convened an expert panel that concluded health system enterprise P&T committees are uniquely positioned to balance clinical value with financial stewardship and minimize practice variation. They issued best practice considerations representing a dynamic framework designed to evolve alongside emerging therapies, evolving technologies, and the ongoing transformation of health systems. Joining us today are two members of the expert panel. We have Connor Hanrahan, AVP, enterprise pharmacy services, medication outcomes and stewardship with Intermountain Health and Prabashni Reddy, who at the time of the panel was the executive director of medication use and policy at Mass General Brigham.   Guest speakers:  Prabashni Reddy, RPh, PharmD, MMedSc (former) Executive Director of Medication Use and Policy Mass General Brigham Connor Hanrahan, PharmD, MHA, MS, BCPS, CPHQ AVP, Medication Policy, Outcomes, and Stewardship Intermountain Health, Enterprise Pharmacy Services Host: Kerry Schwarz, PharmD, MPH   Senior Clinical Manager, Evidence-Based Medicine and Outcomes  Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:02-03:38] The value Prabashni and Conor saw in joining the expert panel [03:39-05:33] What Prabashni and Conor learned from interactions during the expert panel  [05:34-10:55] Intriguing actionable enterprise P&T program insights panelists brought to the table that listeners can use [10:56-14:01] Use of criteria and principles to create successful and broadly applicable best practices [14:56-16:00] How our listeners can put this panel's best practices into action   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Right on the heels of the release of the 2025 AHA guidelines, including one on preferentially using IVs over IOs, comes two RCTs in the same edition of NEJM that compare intial attempts with IVs to IOs in out of hospital cardiac arrest. Dr Jarvis discusses these two papers while answer a listeners question, and tries to put this, and early epinephrine, into context. And he might throw in some commentary about the AHA's recommendations on mCPR and Heads Up CPR.Citations:1. Couper K, Ji C, Deakin CD, et al. A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2025;392(4):336-348. doi:10.1056/NEJMoa24077802. Vallentin MF, Granfeldt A, Klitgaard TL, et al. Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest. N Engl J Med. 2025;392(4):349-360. doi:10.1056/NEJMoa2407616

Thrust onto the public stage at 15 years old after the Taliban's brutal attack on her life, Malala Yousafzai became an international icon for resilience and bravery. Described as a reflection on a life of a woman finally taking charge of her destiny, her memoir Finding My Way has just been published. She joins Anita Rani in the Woman's Hour studio.There's a call to compensate women caught up in the scandal of faulty breast implants manufactured by a French company. The PIP scandal happened in 2012 when it emerged that the implants were filled with industrial silicone instead of medical grade silicone. The implants are far more likely to rupture than others. MPs on the Women's and Equalities Committee have been hearing calls for compensation during their inquiry into the health impacts of breast implants and other cosmetic procedures. Jan Spivey from PIP Action Campaign and Professor Carl Heneghan from The Centre for Evidence Based Medicine join us to discuss this.What if all your dreams come true and you still find yourself a bit grumpy? That's the brilliantly blunt question at the heart of Laura Smyth's stand-up tour, Born Aggy. Laura's journey into comedy wasn't exactly textbook. She left behind a career in teaching, was diagnosed with Stage 3 breast cancer that same year and - just two weeks after finishing treatment - was on stage in Live at the Apollo. She joins Nuala McGovern in the studio.Choreographer and artist Amina Khayyam tells Anita about her new dance-theatre work, Bibi Rukiya's Reckless Daughter, which opens soon in London after a national tour. It explores how patriarchy is enforced not only by men, but across generations of women, within family structures.Singer, actor and performer, Petula Clark's career has spanned over eight decades. She sang to wartime troops in the 40s, was a 1950s child star, became a European musical icon before conquering America with her No 1 hit Downtown. She starred in Hollywood movies alongside Fred Astaire and performed on stage in musicals including The Sound of Music, Sunset Boulevard and most recently Mary Poppins. Her autobiography - Is That You, Petula? is out now and she joins Nuala to look back at her long career.Presenter: Anita Rani Producer: Simon Richardson

If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad To subscribe to my exclusive content on X, please visit my bio at https://x.com/GadSaad _______________________________________ This clip was posted on October 29, 2025 on my YouTube channel as THE SAAD TRUTH_1926: https://youtu.be/0BxHQ1LY3bM _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense.  _______________________________________

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we have Part 2 on EBM updates for intubation. We'll cover induction medications, paralytics, VL vs. DL, using the bougie, confirming ETT placement, and post intubation sedation.  Please see Part 1 for background, predicting difficult BVM/intubation/cricothryotomy, physiologic factors associated with peri-intubation decompensation, preoxygenation, and apneic oxygenation. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

Artificial intelligence, or, AI is on everyone's minds, and we're all still figuring out how to trust it, teach it, and use it responsibly. Today we take a deep dive into how AI is affecting the education of current and future pharmacy students. With us is Jennifer Trujillo, associate Dean for education and professor in the Department of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences on the University of Colorado Anschutz Medical Campus in Aurora, Colorado, and Logan Tinsen, the clinical pharmacy manager and residency program director at Benefis Hospital in Great Falls, Montana.   Guest speakers:  Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM Associate Dean for Education Professor, Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus Logan Tinsen, PharmD, FMPA Clinical Pharmacy Manager and Residency Program Director Benefits Hospitals   Host:   Kerry Schwarz, PharmD, MPH   Senior Clinical Manager, Evidence-Based Medicine and Outcomes  Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:02-03:45] Challenges with AI in pharmacy education [03:46-05:59] The AI adoption spectrum: Pitfalls of extremes between full and limited adoption [06:00-11:18] Approaches to pharmacy education in the early stages of AI [11:19-14:55] Guardrails and safeguards [14:56-16:29] Key takeaways about AI right now for pharmacy educators   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we start a series on EBM updates for intubation. We cover some background, predicting difficult BVM/intubation/cricothryotomy, physiologic factors associated with peri-intubation decompensation, preoxygenation, and apneic oxygenation. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

Send us a textIn this episode of the Incubator Podcast, Dr. Mario Rüdiger, a prominent neonatologist from Germany, shares his journey into the field of neonatology, discussing the differences between European and American practices, the importance of flexibility in adopting new therapies, and the role of evidence in neonatal care. He emphasizes the significance of empowering parents in the NICU and advocates for a family-centered approach to care. The conversation also touches on the future of neonatal education, the impact of podcasting in the field, and the challenges of work-life balance for healthcare professionals. Dr. Rüdiger's insights provide a comprehensive view of the evolving landscape of neonatal care and the importance of advocacy in shaping policies that benefit both patients and practitioners.  Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textWhat if you could hold in your hands a roadmap to the most influential studies that have shaped modern neonatology? In this special episode of The Incubator Podcast, Ben and Daphna sit down with Dr. John Zupancic, Dr. Susanna Hay, and Dr. Roger Soll to discuss the release of their new book, 50 Studies Every Neonatologist Should Know. Together with their co-editors Dr. Barbara Schmidt and Dr. Haresh Kirpalani, the team has distilled decades of neonatal research into an accessible, thoughtfully structured volume designed to guide clinicians, trainees, and educators.The conversation explores the motivation behind the book, the editorial process of selecting just 50 landmark trials from thousands, and the importance of revisiting historical studies to understand how evidence has evolved over time. From the groundbreaking DART trial to the early work of pioneers like Bill Silverman, the authors emphasize not only the science but also the stories, challenges, and human insights that lie behind each study.Whether you are a seasoned neonatologist or just beginning your training, this episode provides a behind-the-scenes look at a project that brings clarity and context to evidence-based practice.

Why does a podcast about capitalism want to talk about science?Modern capitalism and science have evolved together since the Enlightenment. Advances in ship building and navigation enabled the Age of Discovery, which opened up new trade routes and markets to European merchants. The invention of the spinning jinny and cotton in the 18th century spurred textile production. The United States' Department of Defense research and development agency helped create the precursor to the internet. The internet now supports software and media industries worth trillions of dollars. On the flip side, some of America's greatest capitalists and businesses, including Thomas Edison, Henry Ford, and Bell Labs, gave us everything from electricity production to the transistor. Neither science nor capitalism can succeed without the other.However, science's star is now dimming. Part of this is due to political intervention. In the U.S., the federal government has cut funding for scientific research. The Covid-19 pandemic diminished the public's trust in scientific experts, which social media has exacerbated through misinformation. Restrictions on immigration may further hamper scientific research as some of the world's brightest minds lose access to funding and state-of-the-art facilities.But so too has capitalism played a hand in science's struggles. While corporations sponsor a significant portion of funding for scientific research, this funding too often comes with undisclosed conflicts of interest. Or corporate pressure may influence results in other ways.Stanford University professor John Ioannidis is a physician, writer, and one of the world's most-cited scientists. He studies the methodology and sociology of science itself: how the process and standards for empirical research influence findings in ways that some may find inaccurate. His 2005 essay "Why Most Published Research Findings Are False" is one of the most accessed articles in the history of Public Library of Science (PLOS), with more than three million views. Ioannidis joins Bethany and Luigi to discuss the future of the relationship between capitalism and science, how both will have to respond to contemporary politics, and how one even conceptualizes robust measurements of scientific success.Listen:Science for Sale, with David Michaels: Learn how corporate-funded science uses doubt to its patrons' advantage.The Money Behind Ultra-Processed Foods, with Marion Nestle: Examine the role of Big Food in public health.The Capitalisn't of the U.S. COVID Response: Understand the factors that exacerbated the pandemic's fallout for the most vulnerable in society.Read:Food for Thought: An excerpt from the second edition of Marion Nestle's book, Food Politics: How the Food Industry Influences Nutrition and Health.How Conflicts of Interest Shape Trust in Academic Work: What is the impact of various conflicts of interest on readers' trust in academic research findings? What are the implications for academia and policy?There's More Bias Than You Think: To protect the integrity of academia, we must also encourage the injection and consideration of new and contradictory unconflicted ideas.Academic Bias Under the Microscope: That scholarship often reflects conscious and unconscious biases has long been an open secret in academia. What are the sources of industry bias in economic and business research, and possible avenues of mitigation?“Doubt is Their Product”: The Difference Between Research and Academic Lobbying:Reflecting on the intersection of academic economics and policymaking – and advice to young scholars.Watch:John Ioannidis' Keynote at the Stigler Center Antitrust and Competition Conference 2025: Economic Concentration and the Marketplace of IdeasHow Conflicts of Interest Impact the Marketplace of Ideas: WebinarDe-Biasing Academic Research: Panel Discussion at the Stigler Center Antitrust and Competition Conference 2022 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.